FY2026 Earnings Estimate for HALO Issued By Leerink Partnrs

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Leerink Partnrs increased their FY2026 EPS estimates for Halozyme Therapeutics in a research note issued to investors on Wednesday, October 1st. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings of $8.18 per share for the year, up from their previous forecast of $8.11. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share.

A number of other brokerages have also commented on HALO. Benchmark increased their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Weiss Ratings restated a “hold (c+)” rating on shares of Halozyme Therapeutics in a research note on Saturday, September 27th. Morgan Stanley upped their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a report on Monday, August 18th. Finally, JMP Securities lifted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $70.44.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $68.98 on Friday. Halozyme Therapeutics has a fifty-two week low of $42.01 and a fifty-two week high of $79.50. The stock’s 50-day moving average is $70.45 and its two-hundred day moving average is $61.97. The firm has a market cap of $8.07 billion, a P/E ratio of 15.78, a price-to-earnings-growth ratio of 0.40 and a beta of 1.16. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. Halozyme Therapeutics’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of HALO. Wealth Preservation Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth about $32,000. Newbridge Financial Services Group Inc. acquired a new position in Halozyme Therapeutics in the second quarter worth about $32,000. SVB Wealth LLC bought a new position in Halozyme Therapeutics during the first quarter worth about $33,000. Bessemer Group Inc. lifted its stake in Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 207 shares during the period. Finally, Employees Retirement System of Texas acquired a new stake in Halozyme Therapeutics during the second quarter valued at approximately $34,000. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares in the company, valued at $50,648,622.57. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Nicole Labrosse sold 2,227 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the transaction, the chief financial officer directly owned 22,079 shares of the company’s stock, valued at approximately $1,721,058.05. This trade represents a 9.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 128,227 shares of company stock valued at $8,908,195 over the last three months. 2.40% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.